Head and neck squamous cell carcinoma and metachronous second primaries.
To assess the rate of second (or more) primaries after treatment for head and neck squamous cell carcinoma (HNSCC), and survival compared to patients with a single head and neck cancer. A single-center retrospective study was performed in a University Hospital Center in 541 patients between 2002 and 2010. One hundred and forty-one patients (26.06%) presented 172 metachronous cancers. Overall 5-year survival was 20.3% with and 38.1% without metachronous cancer. Median and mean survival were respectively 21.9 and 51 months in patients with a single cancer, versus 13.9 and 26.5 months in case of metachronous cancer. Specific survival was comparable to overall survival. All-cause and specific survival were significantly poorer in metachronous cancer (P=0.001; log-rank α=0.05). At least a quarter of HNSCC patients go on to develop a metachronous second primary. These are of poor prognosis, whatever their location.